FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225000244> ?p ?o ?g. }

• W4225000244 abstract "Friedreich’s ataxia (FRDA) is an autosomal recessive disease caused by an intronic guanine-adenine-adenine (GAA) triplet expansion in the frataxin ( FXN ) gene, which leads to reduced expression of full-length frataxin (1–210) also known as isoform 1. Full-length frataxin has a mitochondrial targeting sequence, which facilitates its translocation into mitochondria where it is processed through cleavage at G 41 -L 42 and K 80 -S 81 by mitochondrial processing (MPP) to release mitochondrial mature frataxin (81–210). Alternative splicing of FXN also leads to expression of N-terminally acetylated extra-mitochondrial frataxin (76–210) named isoform E because it was discovered in erythrocytes. Frataxin isoforms are undetectable in serum or plasma, and originally whole blood could not be used as a biomarker in brief therapeutic trials because it is present in erythrocytes, which have a half-life of 115-days and so frataxin levels would remain unaltered. Therefore, an assay was developed for analyzing frataxin in platelets, which have a half-life of only 10-days. However, our discovery that isoform E is only present in erythrocytes, whereas, mature frataxin is present primarily in short-lived peripheral blood mononuclear cells (PBMCs), granulocytes, and platelets, meant that both proteins could be quantified in whole blood samples. We now report a quantitative assay for frataxin proteoforms in whole blood from healthy controls and FRDA patients. The assay is based on stable isotope dilution coupled with immunoprecipitation (IP) and two-dimensional-nano-ultrahigh performance liquid chromatography/parallel reaction monitoring/high resolution mass spectrometry (2D-nano-UHPLC-PRM/HRMS). The lower limit of quantification was 0.5 ng/mL for each proteoform and the assays had 100% sensitivity and specificity for discriminating between healthy controls ( n = 11) and FRDA cases ( N = 100 in year-1, N = 22 in year-2,3). The mean levels of mature frataxin in whole blood from healthy controls and homozygous FRDA patients were significantly different ( p &lt; 0.0001) at 7.5 ± 1.5 ng/mL and 2.1 ± 1.2 ng/mL, respectively. The mean levels of isoform E in whole blood from healthy controls and homozygous FRDA patients were significantly different ( p &lt; 0.0001) at 26.8 ± 4.1 ng/mL and 4.7 ± 3.3 ng/mL, respectively. The mean levels of total frataxin in whole blood from healthy controls and homozygous FRDA patients were significantly different ( p &lt; 0.0001) at 34.2 ± 4.3 ng/mL and 6.8 ± 4.0 ng/mL, respectively. The assay will make it possible to rigorously monitor the natural history of the disease and explore the potential role of isoform E in etiology of the disease. It will also facilitate the assessment of therapeutic interventions (including gene therapy approaches) that attempt to increase frataxin protein expression as a treatment for this devastating disease." @default.
• W4225000244 created "2022-04-29" @default.
• W4225000244 creator A5007007052 @default.
• W4225000244 creator A5010542220 @default.
• W4225000244 creator A5011868333 @default.
• W4225000244 creator A5023970440 @default.
• W4225000244 creator A5055589307 @default.
• W4225000244 creator A5079384190 @default.
• W4225000244 creator A5080280424 @default.
• W4225000244 creator A5085555480 @default.
• W4225000244 date "2022-04-28" @default.
• W4225000244 modified "2023-09-26" @default.
• W4225000244 title "Simultaneous Quantification of Mitochondrial Mature Frataxin and Extra-Mitochondrial Frataxin Isoform E in Friedreich’s Ataxia Blood" @default.
• W4225000244 cites W1572658279 @default.
• W4225000244 cites W1685989555 @default.
• W4225000244 cites W1922040873 @default.
• W4225000244 cites W1967120996 @default.
• W4225000244 cites W1969169134 @default.
• W4225000244 cites W1971590650 @default.
• W4225000244 cites W1986581289 @default.
• W4225000244 cites W1989239257 @default.
• W4225000244 cites W2007286297 @default.
• W4225000244 cites W2014020549 @default.
• W4225000244 cites W2015566467 @default.
• W4225000244 cites W2016403696 @default.
• W4225000244 cites W2027903172 @default.
• W4225000244 cites W2037195005 @default.
• W4225000244 cites W2037196385 @default.
• W4225000244 cites W2047008648 @default.
• W4225000244 cites W2054659940 @default.
• W4225000244 cites W2056239308 @default.
• W4225000244 cites W2056959197 @default.
• W4225000244 cites W2083814934 @default.
• W4225000244 cites W2084199428 @default.
• W4225000244 cites W2095184629 @default.
• W4225000244 cites W2095269394 @default.
• W4225000244 cites W2103367178 @default.
• W4225000244 cites W2105822562 @default.
• W4225000244 cites W2110864849 @default.
• W4225000244 cites W2110977020 @default.
• W4225000244 cites W2117731710 @default.
• W4225000244 cites W2120039680 @default.
• W4225000244 cites W2123164720 @default.
• W4225000244 cites W2125078806 @default.
• W4225000244 cites W2133622631 @default.
• W4225000244 cites W2134435694 @default.
• W4225000244 cites W2135552919 @default.
• W4225000244 cites W2138881473 @default.
• W4225000244 cites W2158155007 @default.
• W4225000244 cites W2163808951 @default.
• W4225000244 cites W2168176110 @default.
• W4225000244 cites W2492997309 @default.
• W4225000244 cites W2724280825 @default.
• W4225000244 cites W2776731408 @default.
• W4225000244 cites W2900803228 @default.
• W4225000244 cites W3092673148 @default.
• W4225000244 doi "https://doi.org/10.3389/fnins.2022.874768" @default.
• W4225000244 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35573317" @default.
• W4225000244 hasPublicationYear "2022" @default.
• W4225000244 type Work @default.
• W4225000244 citedByCount "3" @default.
• W4225000244 countsByYear W42250002442022 @default.
• W4225000244 countsByYear W42250002442023 @default.
• W4225000244 crossrefType "journal-article" @default.
• W4225000244 hasAuthorship W4225000244A5007007052 @default.
• W4225000244 hasAuthorship W4225000244A5010542220 @default.
• W4225000244 hasAuthorship W4225000244A5011868333 @default.
• W4225000244 hasAuthorship W4225000244A5023970440 @default.
• W4225000244 hasAuthorship W4225000244A5055589307 @default.
• W4225000244 hasAuthorship W4225000244A5079384190 @default.
• W4225000244 hasAuthorship W4225000244A5080280424 @default.
• W4225000244 hasAuthorship W4225000244A5085555480 @default.
• W4225000244 hasBestOaLocation W42250002441 @default.
• W4225000244 hasConcept C104317684 @default.
• W4225000244 hasConcept C153911025 @default.
• W4225000244 hasConcept C1621761 @default.
• W4225000244 hasConcept C169760540 @default.
• W4225000244 hasConcept C185592680 @default.
• W4225000244 hasConcept C203014093 @default.
• W4225000244 hasConcept C2779314966 @default.
• W4225000244 hasConcept C2779369046 @default.
• W4225000244 hasConcept C2780906641 @default.
• W4225000244 hasConcept C28859421 @default.
• W4225000244 hasConcept C53345823 @default.
• W4225000244 hasConcept C55493867 @default.
• W4225000244 hasConcept C86803240 @default.
• W4225000244 hasConceptScore W4225000244C104317684 @default.
• W4225000244 hasConceptScore W4225000244C153911025 @default.
• W4225000244 hasConceptScore W4225000244C1621761 @default.
• W4225000244 hasConceptScore W4225000244C169760540 @default.
• W4225000244 hasConceptScore W4225000244C185592680 @default.
• W4225000244 hasConceptScore W4225000244C203014093 @default.
• W4225000244 hasConceptScore W4225000244C2779314966 @default.
• W4225000244 hasConceptScore W4225000244C2779369046 @default.
• W4225000244 hasConceptScore W4225000244C2780906641 @default.
• W4225000244 hasConceptScore W4225000244C28859421 @default.
• W4225000244 hasConceptScore W4225000244C53345823 @default.
• W4225000244 hasConceptScore W4225000244C55493867 @default.
• W4225000244 hasConceptScore W4225000244C86803240 @default.
• W4225000244 hasFunder F4320332813 @default.

• next